Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters.

Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjö L, Lindahl A, Lundberg PA, Isaksson OG, Lindstedt S, Bengtsson BA

Neuroendocrinology1 Jan 1995Cited by 114 (Europe PMC)

PMID7537355DOI10.1159/000126813PepBankPUB-07537355

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialPharmacokinetics
In adults with GH deficiency, rhGH increased CSF growth hormone from 13.3 +/- 4.4 to 149.3 +/- 22.2 muU/l (p = 0.002).
In plain wordsIn adults with GH deficiency, spinal fluid growth hormone increased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCSF growth hormone
Study
n = 10
Outcome group
Pharmacokinetics · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF growth hormone
13.3 muU/l
before rhGH (+/- 4.4)
CSF growth hormone
149.3 muU/l
during rhGH (+/- 22.2)
P value
0.002
CSF growth hormone change
Source sentences
Summary
In cerebrospinal fluid, the mean concentration of growth hormone increased from 13.3 +/- 4.4 to 149.3 +/- 22.2 muU/l (p = 0.002), during recombinant human growth hormone treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735501
02HumanNon-randomized trialMechanism
In adults with GH deficiency, rhGH increased CSF IGF-I from 0.67 +/- 0.04 to 0.99 +/- 0.10 micrograms/l (p = 0.005).
In plain wordsIn adults with GH deficiency, spinal fluid IGF-I increased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCSF IGF-I
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF IGF-I
0.67 micrograms/l
before rhGH (+/- 0.04)
CSF IGF-I
0.99 micrograms/l
during rhGH (+/- 0.10)
P value
0.005
CSF IGF-I change
Source sentences
Summary
The cerebrospinal fluid IGF-I concentration increased from 0.67 +/- 0.04 to 0.99 +/- 0.10 micrograms/l (p = 0.005) and the IGFBP-3 concentration rose from 13.4 +/- 1.25 to 17.5 +/- 1.83 micrograms/l (p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735502
03HumanNon-randomized trialMechanism
In adults with GH deficiency, rhGH increased CSF IGFBP-3 from 13.4 +/- 1.25 to 17.5 +/- 1.83 micrograms/l (p = 0.002).
In plain wordsIn adults with GH deficiency, spinal fluid IGFBP-3 increased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCSF IGFBP-3
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF IGFBP-3
13.4 micrograms/l
before rhGH (+/- 1.25)
CSF IGFBP-3
17.5 micrograms/l
during rhGH (+/- 1.83)
P value
0.002
CSF IGFBP-3 change
Source sentences
Summary
The cerebrospinal fluid IGF-I concentration increased from 0.67 +/- 0.04 to 0.99 +/- 0.10 micrograms/l (p = 0.005) and the IGFBP-3 concentration rose from 13.4 +/- 1.25 to 17.5 +/- 1.83 micrograms/l (p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735503
04HumanNon-randomized trialMechanism
In adults with GH deficiency, rhGH decreased CSF homovanillic acid from 282.1 +/- 36.0 to 234.3 +/- 26.5 nmol/l (p = 0.02).
In plain wordsIn adults with GH deficiency, spinal fluid homovanillic acid decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseCSF homovanillic acid
Study
n = 10
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF homovanillic acid
282.1 nmol/l
before rhGH (+/- 36.0)
CSF homovanillic acid
234.3 nmol/l
during rhGH (+/- 26.5)
P value
0.02
CSF homovanillic acid change
Source sentences
Summary
The dopamine metabolite homovanillic acid decreased from 282.1 +/- 36.0 to 234.3 +/- 26.5 nmol/l (p = 0.02) and the vasoactive intestinal peptide decreased from 4.1 +/- 0.6 to 3.7 +/- 0.4 pmol/l (p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735504
05HumanNon-randomized trialMechanism
In adults with GH deficiency, rhGH decreased CSF vasoactive intestinal peptide from 4.1 +/- 0.6 to 3.7 +/- 0.4 pmol/l (p = 0.03).
In plain wordsIn adults with GH deficiency, spinal fluid vasoactive intestinal peptide decreased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseCSF vasoactive intestinal peptide
Study
n = 10
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF vasoactive intestinal peptide
4.1 pmol/l
before rhGH (+/- 0.6)
CSF vasoactive intestinal peptide
3.7 pmol/l
during rhGH (+/- 0.4)
P value
0.03
CSF vasoactive intestinal peptide change
Source sentences
Summary
The dopamine metabolite homovanillic acid decreased from 282.1 +/- 36.0 to 234.3 +/- 26.5 nmol/l (p = 0.02) and the vasoactive intestinal peptide decreased from 4.1 +/- 0.6 to 3.7 +/- 0.4 pmol/l (p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735505
06HumanNon-randomized trialMechanism
In adults with GH deficiency, rhGH increased CSF beta-endorphin from 24.4 +/- 1.8 to 29.9 +/- 2.1 pmol/l (p = 0.002).
In plain wordsIn adults with GH deficiency, spinal fluid beta-endorphin increased during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCSF beta-endorphin
Study
n = 10
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Measurements
CSF beta-endorphin
24.4 pmol/l
before rhGH (+/- 1.8)
CSF beta-endorphin
29.9 pmol/l
during rhGH (+/- 2.1)
P value
0.002
CSF beta-endorphin change
Source sentences
Summary
Cerebrospinal fluid immunoreactive beta-endorphin increased from 24.4 +/- 1.8 to 29.9 +/- 2.1 pmol/l (p = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735506
07HumanNon-randomized trialMechanism
In adults with GH deficiency, CSF enkephalins, dynorphin A, norepinephrine and serotonin metabolites, gamma-aminobutyric acid, somatostatin and corticotropin-releasing factor did not change significantly during rhGH treatment.
In plain wordsIn adults with GH deficiency, several spinal fluid peptides and neurotransmitter metabolites did not change significantly during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeCSF enkephalins, dynorphin A, monoamine metabolites, GABA, somatostatin and CRF
Study
n = 10
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
0.25 U/kg/week · 1 monthAs given in this study (human).
Source sentences
Summary
There were no significant changes compared to baseline in the cerebrospinal fluid concentrations of enkephalins, dynorphin A, the norepinephrine metabolite 3-methoxy-4-hydroxyphenyl-ethyleneglycol, the serotonin metabolite 5-hydroxyindoleacetic acid, gamma-aminobutyric acid, somatostatin or corticot…
2 context sentences(design, population, supporting numbers)
Summary · context
In a double-blind, placebo-controlled trial, the effects of recombinant human growth hormone were studied on cerebrospinal fluid concentrations of growth hormone, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), monoamine metabolites, neuropeptides and en…
Summary · context
Twenty patients, 10 patients in each of 2 groups, with adult-onset, growth hormone deficiency were treated for 1 month with recombinant human growth hormone (0.25 U/kg/week) or placebo.
Report a problemFND-0753735507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.